American Century Companies Inc. Buys 4,698 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

American Century Companies Inc. raised its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 99.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,444 shares of the medical instruments supplier's stock after acquiring an additional 4,698 shares during the quarter. American Century Companies Inc. owned approximately 0.17% of Mesa Laboratories worth $1,245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in MLAB. FMR LLC boosted its position in shares of Mesa Laboratories by 34.1% during the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock valued at $51,000 after acquiring an additional 100 shares during the last quarter. Amundi raised its holdings in Mesa Laboratories by 81.6% in the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after purchasing an additional 297 shares in the last quarter. Captrust Financial Advisors acquired a new position in Mesa Laboratories during the 3rd quarter valued at approximately $207,000. Berry Wealth Group LP increased its holdings in Mesa Laboratories by 5.3% in the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock worth $219,000 after buying an additional 83 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in Mesa Laboratories by 4.3% in the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock valued at $231,000 after acquiring an additional 73 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Insider Activity at Mesa Laboratories

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of Mesa Laboratories stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the transaction, the chief executive officer now directly owns 43,337 shares in the company, valued at $5,369,887.67. The trade was a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.40% of the stock is currently owned by insiders.

Mesa Laboratories Trading Down 2.0 %

NASDAQ MLAB traded down $2.27 on Wednesday, reaching $113.26. 12,291 shares of the company were exchanged, compared to its average volume of 38,809. Mesa Laboratories, Inc. has a fifty-two week low of $83.68 and a fifty-two week high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $615.43 million, a P/E ratio of -2.46 and a beta of 0.92. The business's fifty day moving average price is $129.21 and its 200 day moving average price is $128.02.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. Analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be issued a $0.16 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.57%. Mesa Laboratories's dividend payout ratio (DPR) is presently -1.38%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.